JY
ATYR

Jeff Yass’s aTyr Pharma ATYR Stock Holding History

Jeff Yass’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.9K Buy
154,800
+52,100
+51% +$34K ﹤0.01% 12546
2026
Q1 		$80.1K Sell
102,700
-45,400
-31% -$38.3K ﹤0.01% 12461
2025
Q4 		$116K Sell
148,100
-770,900
-84% -$633K ﹤0.01% 11373
2025
Q3 		$662K Buy
919,000
+655,100
+248% +$2.97M ﹤0.01% 8341
2025
Q2 		$1.34M Buy
263,900
+195,200
+284% +$768K ﹤0.01% 6710
2025
Q1 		$207K Buy
68,700
+45,400
+195% +$166K ﹤0.01% 10857
2024
Q4 		$84.3K Buy
23,300
+8,600
+59% +$26K ﹤0.01% 11441
2024
Q3 		$25.9K Buy
+14,700
New +$26.7K ﹤0.01% 11567
2023
Q3 		– Sell
-24,400
Closed -$52.7K – 13168
2023
Q2 		$52.7K Buy
+24,400
New +$53.3K ﹤0.01% 11320
2022
Q2 		– Sell
-37,200
Closed -$199K – 14124
2022
Q1 		$199K Sell
37,200
-25,200
-40% -$143K ﹤0.01% 11248
2021
Q4 		$466K Sell
62,400
-529,100
-89% -$4.42M ﹤0.01% 9396
2021
Q3 		$5.37M Buy
+591,500
New +$3.54M ﹤0.01% 3825

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's ATYR Position: Q2 2026 in Review

Jeff Yass reduced its aTyr Pharma (ATYR) stake by 14% in Q2 2026, selling an estimated $78.2K and leaving 747,039 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #10172.

Jeff Yass first reported a position in ATYR in Q1 2017 and has held it in 17 quarters since. The position peaked at $5.23M in Q1 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Jeff Yass held 747,039 shares of aTyr Pharma worth $446K as of Q2 2026.
  • Jeff Yass sold 119,705 aTyr Pharma shares in Q2 2026, an estimated $78.2K.
  • aTyr Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10172 holding.
  • Jeff Yass first reported a position in aTyr Pharma in Q1 2017 and has held it in 17 quarters since.
  • Jeff Yass's aTyr Pharma position peaked at $5.23M in Q1 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.